ribavirin does show good synergy in the replicon with interferon, so it would be nice to show similar synergy with the DAA(s) in question before moving to combo without interferon in the clinic. that said replicon as you point out likely can't capture that "magic" (as idix's former CEO puts it) it exerts in preventing relapses which is likely immune-mediated as you point out, so it is conceivable to throw it in the DAA mix without nice activity in replicon system
also - and this is not likely to be an issue in the clinic - but ribavirin does bind the polymerase, so in theory mixing it with a polymerase inhibitor could result in a negative drug interaction
Market Data 
Markets 
AI
